METTL3 and hepatocellular carcinoma: Rescue experiment using shRNA‐resistant wild‐type METTL3, but not catalytic mutant METTL3, in METTL3‐depleted HCC cells and in sorafenib‐resistant HCC cells restored their sensitivity to sorafenib under hypoxia, indicating the director role of METL3‐mediated m6A modification in sorafenib resistance of HCC.